Since toxins and HD are unavoidable in uremia, future studies into the possibility of using lactadherin in therapeutic strategies against uremic hypercoagulability, especially in accelerated atherosclerosis and stent thrombosis, are important. This evidence concerns the gene MFGE8 and atherosclerosis.